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Objective:We investigated the relationship between serum prostaglandin E2 and intraoperative blood pressure in
pediatric cardiac surgery with modified ultrafiltration.
Methods: In 35 consecutive patients (31.6  26.8 months, 0.4–111 months, 10.9  5.5 kg, 2.9–23.8 kg) who
underwent cardiac surgery with modified ultrafiltration, we measured intraoperative serum prostaglandin E2
changes and effluent prostaglandin E2, assessed the relationship between serum prostaglandin E2 and intraoper-
ative hemodynamic parameters, and performed subset analyses to compare patients with low (<10 kg, n ¼ 18)
and high (>10 kg, n ¼ 10) weights.
Results: During cardiopulmonary bypass, systolic blood pressure decreased from 80.8 15.2 to 60.5 11.3 mm
Hg (P = .00000002979) and serum prostaglandin E2 increased from 16.6 8.7 to 58.8 53.3 pg/mL (P = .002).
During modified ultrafiltration, although central venous pressure and catecholamine dosage transited at the same
levels, systolic blood pressure increased from 60.5 11.3 to 83.4 14.1 mm Hg (P = .00000002979) and serum
prostaglandin E2 decreased from 58.8 53.3 to 21.1 11.6 pg/mL (P = .001), with negative correlation between
serum prostaglandin E2 and systolic blood pressure (R¼0.392,P = .0000277723) and 15,700 10,700 pg (1790
 2230 pg/kg) prostaglandin E2 removed during modified ultrafiltration. Decrease in serum prostaglandin E2 was
significantly higher in low-weight patients (51.8 58.4 pg/mL) than in high-weight patients (15.7 30.1 pg/mL).
Conclusion: Removal of prostaglandin E2 is one reason for increased blood pressure during modified ultrafiltra-
tion, with the effect more marked in low-weight patients.
Cardiopulmonary Support Yokoyama et alModified ultrafiltration (MUF) was developed as a method
to reduce the adverse effects of cardiopulmonary bypass
(CPB) in pediatric patients.1 In pediatric cardiac surgery
with CPB, MUF has been reported not only to reduce total
body water and decrease pulmonary vascular resistance
but also to increase blood pressure (BP).2 The mechanism
for the increase in BP during MUF, however, remains un-
clear. The removal of interleukins 6 and 83 and endothelin
14 during MUF was reported in previous studies; however,
these changes could not explain the increase in BP during
a short period of MUF. In this study, we hypothesized that
a major cause of the increase in BP is removal of some va-
sodilator by MUF. We therefore investigated the effects of
MUF on the relationship between the serum prostaglandin
E2 (PGE2) level that is activated through exposure of blood
to artificial material during CPB and intraoperative BP in
pediatric cardiac surgery.
MATERIALS AND METHODS
In this study, we assessed 35 consecutive patients who underwent pedi-
atric cardiac surgery with CPB and MUF from October 2005 to September
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doi:10.1016/j.jtcvs.2008.09.017730 The Journal of Thoracic and Cardiovascular Su2007. Informed consent to measure the serum PGE2 level and the PGE2
level in the MUF discharge had been obtained from the parents. The age,
weight, and operative procedure data are shown in Table 1. Exclusion cri-
terion was body weight greater than 25 kg to ensure investigation of a pedi-
atric population.
For pediatric cardiac surgery, we generally use four kinds of CPB circuit
adapted for different body weights. In this study, CPB was performed with
an SS circuit (priming volume 350 mL/circuit; Senko Medical Co, Ltd,
Osaka, Japan; artificial lung baby-RX; Terumo Corporation, Tokyo, Japan)
for body weights smaller than 7 kg, an S circuit (priming volume 500 mL/
circuit; Senko; artificial lung D-902 Lilliput II; Dideco SpA, Mirandola,
Italy) for body weights between 7 and 20 kg, and an M circuit (priming vol-
ume 700 mL/circuit; Senko; artificial lung CAPIOX RX-15; Terumo) for
body weights greater than 20 kg. The CPB flow was maintained at 2.8 L/
(m2/min) during cardiac arrest, and an a-blocker (chlorpromazine) was
administered several times to a total dosage of 2 to 4 mg/kg. Initial blood
priming was performed when the predicted hematocrit during CPB was
lower than 15%, which was the criterion in a previous study.5 Blood trans-
fusion during CPB was performed to ensure a hematocrit greater than 30%
at the end of the CPB. Cardiac arrest was obtained by crystalloid cardiople-
gia with added albumin. The CPB time, aortic crossclamp time, and amount
of intraoperative blood transfusion are also shown in Table 1.
MUFwas performed with a hemoconcentrator (CF04; JMS Co, Ltd, Hir-
oshima, Japan) connected to the CPB circuit in all cases. After CPB, we per-
formed MUF through aortic and inferior venous caval cannulas with the
same routes used for CPB. The blood was taken from the body through
the aortic cannulas and hemofiltered. The remaining blood in the CPB res-
ervoir and the hemofiltered blood were returned to the body through the
inferior venous caval cannula. The MUF flow was 10 mL/(kg/min), and
the time was 15 minutes. Diluted ultrafiltration with 1000 mL crystalloid
solution was performed concomitantly during the CPB.
Many chemomediators are increased by an inflammatory reaction during
pediatric heart surgery with CPB, and these chemomediators could act as
vasodilators. A kallikrein–kinin system is one of the inflammatory systems,
and prostaglandin E2 (PGE2) is one of the substances produced throughrgery c March 2009




BP ¼ blood pressure
CPB ¼ cardiopulmonary bypass
CVP ¼ central venous pressure
DD ¼ dopamine dosage
HR ¼ heart rate
MUF ¼ modified ultrafiltration
PGE2 ¼ prostaglandin E2
activation of the kallikrein–kinin system during CPB (Figure 1). PGE2 has
a low molecular weight and thus is removed through the membrane of the
filter. We therefore measured the serum PGE2 level at the following four
times (n ¼ 28): before (before CPB) and after (end CPB) the CPB, after
the MUF (end MUF), and after the operation (postoperative). Changes in
systolic BP measured by an arterial line, central venous pressure (CVP)
measured by a central venous catheter, heart rate (HR), and dopamine dos-
age (DD) were assessed from anesthesia records at the same four times as
the measurement of the serum PGE2 level. Additionally, to confirm that
PGE2 had been removed to MUF discharge, the PGE2 level in the discharge
and the total PGE2 removed into the discharge duringMUFwere also inves-
tigated (n ¼ 12).
Correlation analyses between the serum PGE2 level and BP, CVP, HR,
and DD and between BP and CVP, HR, and DD were performed. Because
the adverse effects of CPB are increased in low-weight patients,6-10 we di-
vided the patients into two groups by body weight: less than 10 kg (group L,
n ¼ 18) and greater than 10 kg (group H, n ¼ 10). Subset analyses between
the two groups were performed.
After collection, blood samples were centrifuged at 3000 rpm for 5 min-
utes. Plasma was then separated and stored at 70C until analysis.
Discharge samples were treated in the same way as blood samples. The
PGE2 level was measured with a commercially available radioimmunoassay
kit (PerkinElmer Life and Analytical Sciences, Inc, Waltham, Mass).
Comparisons between two values were performed with unpaired 2-tailed
t tests for the means of normally distributed variables and Wilcoxon rank
sum tests for skewed data. Correlation coefficients were used to assess the
correlations between BP and vasodilator level. A correlation coefficient R
between0.30 and 0.30 was considered to indicate a poor correlation. All
the statistical analyses were performed with the statistical software package
SPSS 12.0 J (SPSS Inc, Chicago, Ill) software for Windows (Microsoft Cor-
poration, Redmond, Wash). All data are expressed as mean  SD.
RESULTS
The HR increased during CPB from 126  18 beats/min
before CPB to 149  24 beats/min at end CPB (P =
.0000356305), and no significant differences were observed
after end MUF CPB (146  21 beats/min postoperative 149
 24 beats/min). The CVP showed no significant changes
during the procedure (7.8  2.1 mm Hg before CPB, 9.1
 3.5 mm Hg at end CPB, 9.4  4.1 mm Hg at end MUF,
and 10.3  3.6 mm Hg postoperative). The DD increased
from 0.5  1.6 mg/(kg/min) before CPB to 6.5  2.3 mg/
(kg/min) at end CPB (P = .0000000000000000008262).
No significant differences, however, were observed after
CPB (end MUF 6.3  2.1 mg/[kg/min], postoperative 6.0
 1.9 mg/[kg/min].
The systolic BP decreased during CPB from 80.8  15.2
mm Hg before CPB to 60.5  11.3 mm Hg at end CPBThe Journal of Thoracic and C(P = .00000002979). During MUF, however, systolic BP
increased significantly to 83.4  14.1 mm Hg at end MUF
(P = .000000002802). After that, no significant difference
was observed between end MUF and postoperative (84.0 
14.5 mm Hg) values (Figure 2).
The serum PGE2 level increased during CPB from 16.6
8.7 pg/mL before CPB to 58.8  53.3 pg/mL at end CPB
(P = .002). During MUF, however, the serum PGE2 level
decreased significantly to 21.1  11.6 pg/mL at end MUF
(P = .001); it also showed a tendency to be lower at the post-
operative point (15.4  9.7 pg/mL, P ¼ .06) than at end
MUF (Figure 3). The transitional pattern seen Figure 3 (se-
rum PGE2) is much like a reversal of the transitional pattern
seen in Figure 2 (systolic BP).
The mean amount of the discharge from MUF, the PGE2
level in the MUF discharge, total PGE2 in the MUF dis-
charge, and PGE2 in MUF discharge per body weight are
shown in Table 2. During MUF, a large quantity of PGE2
was removed to the MUF discharge by ultrafiltration.
In correlation analyses, there was a significant negative
correlation between serum PGE2 level and systolic BP
(R ¼0.392, y ¼0.1801xþ79.7, P< .001; Figure 4). Al-
though analyses between other parameters were performed,
there were no correlations between serum PGE2 level and di-
astolic BP, CVP, HR, and DD or between BP (systolic and
diastolic) and CVP, HR, and DD. During MUF, the serum
TABLE 1. Patient profiles
Age (mo, mean  SD and range) 31.6  26.8 (0.4–111)
Weight (kg, mean  SD and range) 10.9  5.5 (2.9–23.8)
Cardiopulmonary bypass time
(min, mean  SD and range)
93.7  50.4 (41–300)
Aortic crossclamp time (min, mean  SD
and range)
45.6  29.4 (14–160)
Blood transfusion (mL, mean  SD
and range)
339  269 (0–1045)
Operative procedures (No.)
Ventricular septal defect closure 14
Atrial septal defect closure 3
Fontan operation 3
Tetralogy of Fallot repair 2
Bidirectonal Glenn shunt 2
Ross procedure 1
Tricuspid valve closure 1
Jatene operation 1
Atrioventricular septal defect repair 1
Truncus arteriosus repair 1
Partial anomalous pulmonary venous
connection repair
1
Cor triatriatum repair 1
Left ventricle–right atrium shunt closure 1
Doty procedure 1
Pulmonary atresia with intact ventricular
septum repair
1
Right ventricular outflow tract stenosis
release
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PPGE2 level was lower and the systolic BP was higher in
almost all patients (Figure 5).
In subset analyses, the blood transfusion per body weight
(67.7  42.8 mL/kg in group L vs 21.2  29.3 mL/kg in
group H), the priming volume per body weight (58.8 
17.1 mL/kg in group L vs 35.2  7.0 mL/kg in group H),
and the area of CPB circuit per body weight (0.35  0.11
m2/kg in group L vs 0.22  0.05 m2/kg in group H) were
all significantly larger in group L than in group H (P<.001).
In each group, systolic BP decreased during CPB, from
73.9  10.7 mm Hg in group L and 89.7  15.8 mm Hg
in group H before CPB to 57.5  12.1 mm Hg in group L
and 64.6  9.3 mm Hg in group H at end CPB (P =
.0000836278984 in group L and .00000603 in group H),
and systolic BP in group Hwas higher than in group L before
CPB (P = .002). During MUF, systolic BP in each group in-
creased, to 82.4  12.3 mm Hg in group L and 85.2  15.9
mmHg in group H at endMUF; values were thereafter main-
tained at the same level to the postoperative measurement
(87.1  17.0 mm Hg in group L and 81.9  11.6 mm Hg
in group H).
In group L, the serum PGE2 level increased significantly
during CPB from 16.7  8.6 before CPB to 72.8  58.1
pg/mL at end CPB (P = .000758); in group H, however,
there was no significant difference between values of 15.6
 9.2 pg/mL before CPB and 32.5  30.8 pg/mL at end
CPB. At end CPB, the serum PGE2 level was significantly
higher in group L than in group H (P = .02). In group L,
the serum PGE2 level decreased significantly during MUF
to 23.9  12.5 pg/mL at end MUF (P = .04); in group H,
however, this value was not significantly lower at end
MUF (16.2  7.6 pg/mL). After that, no significant differ-
ences were observed between end MUF and postoperative
values (17.1  11.0 pg/mL in group L and 12.4  5.9 pg/
mL in group H).
FIGURE 1. Kallikrein–kinin system and prostaglandin E2.
FIGURE 2. Change in systolic blood pressure during operation. Asterisk
indicates P< .01. MUF, Modified ultrafiltration; CPB, cardiopulmonary
bypass; Postop, after operation.
FIGURE 3. Change in serum prostaglandin E2 level during operation.
Asterisk indicates P< .01. MUF, Modified ultrafiltration; CPB, cardiopul-
monary bypass; Postop, after operation.
TABLE 2. Prostaglandin E2 in the modified ultrafiltration discharge
MUFD (mL) 882  337
PGE2 level (pg/mL) 18.8  11.5
PGE2 in MUFD (pg) 15,700  10,700
Ratio of PGE2 in MUFD to body weight (pg/kg) 1790  2230
All values are mean SD.MUF,Modified ultrafiltration discharge; PGE2, prostaglan-
din E2.
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PIn correlation analyses, although there was a significant
negative correlation between serum PGE2 level and systolic
BP in group L (R ¼0.433, P< .001, y ¼0.191xþ82.3),
there was no significant correlation in group H. The decrease
in serum PGE2 during MUF was larger in group L than in
group H (51.8  58.4 pg/mL in group L vs 15.7  30.1
pg/mL in group H, P = .04), and the amount of PGE2 in
the MUF discharge per body weight was also larger in group
L than in group H (3020  2550 pg/kg in group L vs 930 
420 pg/kg in group H, P ¼ .1) (Figure 6).
DISCUSSION
MUF has been reported to have several clinical benefits:
increasing intraoperative BP,11,12 reducing the incidence
of pleural or pericardial effusion, and shortening hospital
stay13 and duration of ventilatory support.14 With regard
to the reason that MUF induces these clinical improvements,
two major contrasting effects can be suggested, ‘‘concentra-
tion’’ or ‘‘removal’’ of some factor or factors in the blood.
For example, increases in the hematocrit, fibrinogen, or total
plasma protein15,16 during MUF would be brought about by
concentration, whereas decreases in interleukin 6 or 8 or in
tumor necrosis factor a3 would occur through removal.
Although it has been suggested that the increase in BP
duringMUFmight result in part from improvements in myo-
cardial contractility associated with a reduction in myocar-
dial water content,2 the precise mechanism for any
increase in BP remains unclear. During MUF, the removal
of serum PGE2 could decrease cardiac index in response
to an increase in cardiac afterload. Although systolic BP in-
creased during MUF in this study, we did not examine
whether cardiac index increased. A previous study, how-
ever, showed that ventricular systolic function improved
during MUF as a result of reduced myocardial edema.17
We suppose that increased cardiac index would be brought
by improved ventricular function despite increased afterload
caused by removal of PGE2 duringMUF. An earlier study of
ours showed that systolic BP was not correlated with in-
creased hematocrit after MUF, and there was also no corre-
lation between the percentage increases in systolic BP and
hematocrit, suggesting that the rise in hematocrit was un-
likely to be responsible for the increased BP after MUF.11
To investigate the major reason for the increase in BP during
MUF, in this study we therefore paid attention to another ef-
fect, the removal of a major vasodilator.
PGE2 production is stimulated by the kallikrein–kinin
system,18 which is activated through the exposure of blood
to artificial materials during CPB.19,20 Additionally, PGE2
is a major intrinsic vasodilator, and a relationship has been
reported between increased serum PGE2 levels and de-
creased BP in patients with intraoperative hypotension under
conditions of CPB21 and hemodialysis.22 As in a previous
report of coronary artery bypass grafting with CPB in adult
patients,23 our study found that the serum PGE2 level in-
creased and systolic BP decreased significantly during
CPB in pediatric patients. In contrast, during MUF, the
FIGURE 4. Correlation between serum prostaglandin E2 level and systolic
blood pressure during operation. There was negative correlation between
serum prostaglandin E2 level and systolic blood pressure (R ¼ 0.392,
y ¼0.1801xþ79.7, P< .01).
FIGURE 5. Changes in serum prostaglandin E2 levels and systolic blood
pressure during modified ultrafiltration (MUF). In almost all cases, serum
prostaglandin E2 level decreased and systolic BP increased during modified
ultrafiltration.
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Pserum PGE2 level decreased and systolic BP increased sig-
nificantly. Additionally, with respect to the relationship
between serum PGE2 level and systolic BP, there was
a significant negative correlation.
DuringMUF, we used the JMS CF04 membrane for ultra-
filtration; this has a screening coefficient that allows the pas-
sage of 90% of molecules 5000 Da in molecular size and
50% of molecules 10,000 Da in molecular size. PGE2 (352
Da in molecular size) will theoretically be removed almost
entirely through the membrane during ultrafiltration. The se-
rum PGE2 level in our study, however, remained above the
reference range even after MUF. Possible explanations for
this are that PGE2 production may be increased under re-
warming of body temperature duringMUF24 and that limited
MUF flow can not ultrafilter all the body’s blood.
In this study, a large amount of PGE2, 15700  10700 pg
(1790  2230 pg/kg) was removed by discharge during
MUF, while at the same time systolic BP increased. In the
light of these results, there is strong evidence that one reason
for the decrease in serum PGE2 is removal by MUF. The
predicted total amount of PGE2 decreased during MUF,
however, was as follows: 10.9 (mean body weight in
kilograms) 3 80 (mean circulated blood in mL/kg) 3 (58.8
21.1 [mean serum PGE2 level during MUF in pg/mL]) ¼
32,874 pg. Therefore about 50% of the predicted total
amount of PGE2 would have been expected to be removed
FIGURE 6. Subset analysis by body weight. Asterisk indicates P< .01.
Group L, Patients with body weight<10 kg; Group H, patients with body
weight>10 kg; MUF, modified ultrafiltration; N.S., not significant; CPB,
cardiopulmonary bypass; Postop, after operation.734 The Journal of Thoracic and Cardiovascular Suthrough the ultrafiltration membrane during MUF in this
study. The rest of the decrease in PGE2 during MUF would
have to be due to inactivation or removal by other means,
such as short-term inactivation by enzymatic action25 in the
lungs,26 excretion to urine,27 and adsorption onto the mem-
brane of the ultrafiltration or artificial CPB circuit, as with
cytokine removal by a polymethymethacrylate membrane
hemofilter.28 Although in our method of MUF (performed
with blood derived from the aorta and returned into the infe-
rior vena cava) the pulmonary to systemic perfusion ratio the-
oretically could become higher duringMUF than after MUF,
which might bring about greater lung inactivation of serum
PGE2, we unfortunately have no data on this. Furthermore,
we did not measure preoperative PGE2 level in this study.
A previous study of evaluating the serum PGE2 level, how-
ever, showed that mean serum PGE2 level before oral PGE2
administration was 45  33 pg/mL in infants 27  9.0 days
old with pulmonary atresia and patent ductus arteriosus,29
and mean serum PGE2 level during the first 2 days after birth
was 12.4 6.8 pg/mL in patients with patent ductus arterio-
sus.30 To investigate the effect of the difference in morphol-
ogy, we performed another subset analysis of the patients
with univentricular morphology (n ¼ 6) and biventricular
morphology (n ¼ 22). The results showed that the increase
in serum PGE2 level and the decrease in systolic BP during
CPB tended to be lower in the patients with univentricular
morphology than in those with biventricular morphology.
We suspect that the reason for the tendency for serum
PGE2 to be lower in the patientswith univentricularmorphol-
ogy may be increased pulmonary blood flow from collateral
arteries developed as a result of preoperative cyanosis. Fur-
ther investigation to clarify the mechanism of the decrease
in serum PGE2 level during MUF is therefore warranted.
It has been reported that large priming volumes produce
deleterious hemodynamic effects and postoperative cardio-
pulmonary dysfunction.6,7 In our subset analysis by body
weight, the amount of blood transfused per body weight,
priming volume per body weight, and area of CPB circuit
per body weight were larger in group L patients (<10 kg)
than in group H patients. Previous studies have demon-
strated that increased priming volume8,9 or blood product
transfusion10 enhances inflammatory response to CPB. It
was suggested that the greater invasiveness of using CPB
in low-weight patients would result in an increased serum
PGE2 level from the greater production of PGE2 that in
turn produces a greater decrease in BP. Interestingly, the de-
crease of serum PGE2 during MUF was larger in group L
than in group H; this because the increased serum PGE2
levels of the smaller patients decreased to the same level
as those of the other patients after MUF. These results sug-
gest that the effect of PGE2 removal by MUF on increased
serum PGE2 levels would be greater in low-weight patients.
Several limitations of this study should be noted. This
study was not randomized and did not have a control group,rgery c March 2009
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Pbecause it is our policy that MUF should be performed for all
pediatric patients undergoing cardiac surgery with CPB and
that the benefits of MUF must be provided to all these pa-
tients. In this study, the circuits, priming volumes, morphol-
ogy, pulmonary to systemic perfusion ratio, age, and weight
were not standardized, because the number of patients was
not large enough. There were the problems of the relatively
small size of the study with a diverse range of anomalies
and widely range of age and weight. This was a pilot study
to define the effectiveness of theMUF and to examine the re-
moval and reduction in PGE2 during MUF; standardization
of these factors should therefore be performed in the future.
Although statistical significance was obtained, the SD of se-
rum PGE2 at the end of CPB became large, because various
types of patients with various ages, body weights, and diag-
noses (many pathologies, with univentricular as well as
biventricular physiology) were included in our study. An un-
controlled biasmay have been induced, because CPB circuits
change according to the body surface area of the patient. In
this study, the circuits, priming volumes, morphology, and
pulmonary to systemic perfusion ratio were not standardized,
because the number of patients was not large enough. Al-
though BP is regulated by various vasoactive substances,
only PGE2 was measured in our study, and we did not assess
whether the cardiac index might be improved during MUF
because of a reduction in cardiac edema.
In conclusion, serum PGE2 level decreased and systolic
BP increased during MUF, with no change in the CVP
and DD. There was a negative correlation between intrao-
perative serum PGE2 levels and systolic BP. A large quantity
of PGE2 was filtered out duringMUF, resulting in a decrease
in serum PGE2. These results suggested that the decrease in
serum PGE2 levels caused by removal of PGE2 is one of the
reasons for the increase in BP seen during MUF. PGE2 re-
moval by MUF is more effective in low-weight patients
and may counteract the more marked increase in serum
PGE2 levels caused by CPB in these patients.
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